Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.
Milazzo L, Rusconi S, Testa L, La Seta-Catamancio S, Galazzi M, Kurtagic S, Citterio P, Gianotto M, Grassini A, Adorni F, d'Arminio-Monforte A, Galli M, Moroni M. Milazzo L, et al. Among authors: adorni f. J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):101-3. doi: 10.1097/00042560-199909010-00013. J Acquir Immune Defic Syndr. 1999. PMID: 10534153 Clinical Trial. No abstract available.
Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.
Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Piazza M, Vaccarezza M, d'Arminio Monforte A, Moroni M. Galli M, et al. Among authors: adorni f. J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):21-31. doi: 10.1097/00126334-200201010-00003. J Acquir Immune Defic Syndr. 2002. PMID: 11782586
Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy.
Bini T, Testa L, Chiesa E, Adorni F, Abeli C, Castelnuovo B, Melzi S, Sollima S, Bongiovanni M, d'Arminio Monforte A. Bini T, et al. Among authors: adorni f. J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):115-22. doi: 10.1097/00126334-200006010-00005. J Acquir Immune Defic Syndr. 2000. PMID: 10935686 Clinical Trial.
Changes in the incidence of severe thrombocytopenia and its predisposing conditions in HIV-infected patients since the introduction of highly active antiretroviral therapy.
Franzetti M, Adorni F, Oreni L, Van Den Bogaart L, Resnati C, Milazzo L, Antinori S, Galli M, Ridolfo AL. Franzetti M, et al. Among authors: adorni f. J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):493-8. doi: 10.1097/QAI.0000000000000347. J Acquir Immune Defic Syndr. 2014. PMID: 25230291
Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.
d'Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, Abeli C, Rusconi S, Sollima S, Balotta C, Musicco M, Galli M, Moroni M. d'Arminio Monforte A, et al. Among authors: adorni f. AIDS. 1998 Sep 10;12(13):1631-7. doi: 10.1097/00002030-199813000-00010. AIDS. 1998. PMID: 9764782 Clinical Trial.
CD4 cell counts at the third month of HAART may predict clinical failure.
d'Arminio Monforte A, Testori V, Adorni F, Castelnuovo B, Bini T, Testa L, Moscatelli G, Chiesa E, Rusconi S, Abeli C, Sollima S, Musicco M, Meroni L, Galli M, Moroni M. d'Arminio Monforte A, et al. Among authors: adorni f. AIDS. 1999 Sep 10;13(13):1669-76. doi: 10.1097/00002030-199909100-00010. AIDS. 1999. PMID: 10509568
96 results